U.S. Markets open in 9 hrs 3 mins

Should Benitec Biopharma Limited (ASX:BLT) Be Your Next Stock Pick?

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to their future outlook. In the case of Benitec Biopharma Limited (ASX:BLT), it is a company that has been able to sustain great financial health, trading at an attractive share price. Below, I've touched on some key aspects you should know on a high level. For those interested in digger a bit deeper into my commentary, take a look at the report on Benitec Biopharma here.

Flawless balance sheet and undervalued

BLT's ability to maintain an adequate level of cash to meet upcoming liabilities is a good sign for its financial health. This indicates that BLT has sufficient cash flows and proper cash management in place, which is a key determinant of the company’s health. Looking at BLT's capital structure, the company has no debt on its balance sheet. It has only utilized funding from its equity capital to run the business, which is typically normal for a small-cap company. BLT has plenty of financial flexibility, without debt obligations to meet in the short term, as well as the headroom to raise debt should it need to in the future. BLT is currently trading below its true value, which means the market is undervaluing the company's expected cash flow going forward. According to my intrinsic value of the stock, which is driven by analyst consensus forecast of BLT's earnings, investors now have the opportunity to buy into the stock to reap capital gains. Compared to the rest of the biotechs industry, BLT is also trading below its peers, relative to earnings generated. This supports the theory that BLT is potentially underpriced.

ASX:BLT Price Estimation Relative to Market, May 9th 2019

Next Steps:

For Benitec Biopharma, I've put together three key factors you should look at:

  1. Future Outlook: What are well-informed industry analysts predicting for BLT’s future growth? Take a look at our free research report of analyst consensus for BLT’s outlook.
  2. Historical Performance: What has BLT's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of BLT? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.